Sector News

GSK's new pharma head to join in September after AstraZeneca tussle

June 19, 2017
Life sciences

GlaxoSmithKline has struck a deal for Luke Miels to start as its new head of pharmaceuticals in September, following a lengthy dispute over his contract with his former employer AstraZeneca.

Britain’s biggest drugmaker poached Miels in January in the first major appointment by incoming GSK Chief Executive Emma Walmsley. But his arrival was stalled by an AstraZeneca lawsuit disputing when he could join.

GSK said on Monday it had now struck an agreement with AstraZeneca for Miels to start on Sept. 4, avoiding the need for a court case over his contract.

Miels had headed AstraZeneca’s European business and his defection was a blow to the company, which has seen a number of senior management departures.

For Walmsley, his appointment is viewed as pivotal, since he will be a key lieutenant as she tries to steer GSK’s core pharmaceuticals business towards improved productivity and higher profits.

Originally, GSK had hoped for a lengthy handover period during which Miels would work alongside outgoing pharma head Abbas Hussain. However, the delay in his arrival means this will not now be possible.

Miels, who has both commercial and scientific experience after working at AstraZeneca, Roche and Sanofi, will arrive as GSK is looking to a new wave of drugs to offset the decline of lung treatment Advair.

Walmsley, who became GSK CEO on April 1, worked in marketing and management at L’Oreal for 17 years before joining the drugmaker and has her roots a long way from the pharmaceutical lab bench.

That has raised doubts among some investors about her insight into prescription drugs and she is expected to rely heavily on advice from Miels, as well as GSK’s research boss Patrick Vallance.

By Ben Hirschler

Source: Reuters

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.